Press releases
2016-03-22 – Press release
Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’
- Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications
- Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m
- Initiation of first clinical trials expected in 2017
read more …
2016-03-22 – Press release
Topas Therapeutics Raises EUR 14 Million to Treat Immunological Disorders
- Causal therapies based on novel approach for antigen-specific tolerance induction
- Significant opportunities through near term clinical proof-of-concept (“POC”)
- Strong strategic syndicate includes Epidarex Capital, EMBL Ventures, Gimv, and Evotec AG
read more …
